4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma

Main Inclusion Criteria: * Advanced stage hepatocellular carcinoma * Patients exhibiting progressive disease under Sorafenib treatment * Child-Pugh class A and B. Only patients with Child-Pugh index class B of not more than 7 will be included * ECOG performance status 0, 1 or 2 * Precedent first-line treatment with Sorafenib minimum continuous dosing of 400 mg per day for at least 8 weeks Main Exclusion Criteria: * Previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1) - any cancer curatively treated \> 3 years prior to entry is permitted * Renal failure requiring hemo- or peritoneal dialysis * Known central nervous system (CNS) tumors including symptomatic brain metastasis * Child-Pugh index class B in combination with more than slight ascites or hepatic encephalopathy \> Grade I * Pregnant or breastfeeding women * Sorafenib intolerance * Major surgery within the last 4 weeks